Axsome Crosses $1 Billion Annualized Revenue on AUVELITY Surge

Axsome Therapeutics crossed a $1 billion annualized revenue run rate for the first time, reporting $260 million in third-quarter revenue on the strength of its AUVELITY franchise. The figure, disclosed at the Guggenheim Healthcare Innovation Conference, rests on AUVELITY sales of $208 million, up 53% year over year and 15% quarter over quarter.

Chief Financial Officer Nick Pizzie said quarterly revenue exceeded a $1 billion annualized run rate for the first time. The growth is being driven by two approved uses of AUVELITY: major depressive disorder and Alzheimer's disease agitation (a state of aggression or distress in dementia patients).

What is behind the prescription numbers?

Pizzie said new-to-brand prescriptions (the first prescription a patient receives for a drug, rather than a refill) are a leading indicator of future AUVELITY growth. The trajectory is unambiguous:

• Weekly new-to-brand prescriptions averaged 2,400 in the first quarter, 3,000 in the second and 3,550 in the third.
• October was tracking at 3,800 per week.
• Among patients aged 65 and older, monthly new-to-brand prescriptions rose from roughly 1,000 before the Alzheimer's agitation approval to 3,600 by the end of September.

He said it typically takes a couple of quarters for new prescriptions and subsequent refills to show up fully in total prescription volumes. Axsome expects continued growth in the underlying depression business and accelerated growth in Alzheimer's agitation, though it has not provided specific quarterly sales guidance.

The company expanded its sales force from approximately 270 representatives to around 650 over roughly six months, Pizzie said. Chief Operating Officer Mark Jacobson added that a dedicated team is working in long-term care, where prescribing develops more slowly because facilities require education and systems activation.

On pricing, the gross-to-net adjustment (the gap between list price and what the company actually collects after rebates and discounts) improved to the mid-to-high 40% range in the third quarter. Pizzie said it could rise in the fourth quarter and suggested using the corresponding 2026 quarters as a starting point for 2027 estimates. Changes in Medicare mix or coverage arrangements could affect the outcome.

How healthy is the rest of the portfolio?

SUNOSI, Axsome's treatment for excessive daytime sleepiness, generated approximately $46 million in quarterly revenue. SYMBRAVO, for acute migraine, contributed $3.9 million. The company also recognized an approximately $8.5 million milestone during the quarter.

Axsome ended the period with $314 million in cash and a $13 million net loss. Pizzie said the company was cash-flow positive for the first time in the quarter, on a basis excluding stock-based compensation and other one-time items. He cautioned that Axsome had not projected sustained cash-flow positivity; the priority remains growing revenue across its three brands, which span four approved indications alongside a pipeline of 10 programs.

What does 2027 hold?

The FDA decision date for AXS-12, a candidate for cataplexy (sudden muscle weakness) in narcolepsy, is May 1, 2027. Jacobson said the review was proceeding as expected and pre-launch activities were underway. Executives noted Axsome could deploy its existing sleep-disorder sales infrastructure if the product is approved.

First-quarter 2027 will also bring results from a SUNOSI study in binge eating disorder. Jacobson said a statistically significant result on the primary endpoint would constitute a positive study, but a second trial would still be required before pursuing an application for that indication.

Other SUNOSI work spans depression with excessive daytime sleepiness, attention-deficit/hyperactivity disorder and shift work disorder. The depression study is event-driven, making its readout timing uncertain, though enrollment should complete in 2027.

Axsome, headquartered in New York and led by founder, chairman and chief executive officer Herriot Tabuteau, focuses on central nervous system disorders. A $1 billion run rate does not settle the cash-flow question. It does, however, make the question considerably more comfortable to ask.